source
- Servier to acquire Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billionFrench pharma group Servier announced it will purchase Edgewise Therapeutics' muscular dystrophy business. The transaction is valued at up to $2.65 billion, comprising a $1.55 billion upfront cash…
- AstraZeneca reports promising triplet therapy results in liver cancer subgroupAstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…